Eli Lilly
-
{
- All
- News
- Videos
-
Eli Lilly Launches Alzheimer's Drug Lormalzi Priced At Rs 91,688 Per Vial In India
Eli Lilly has launched Lormalzi (donanemab) in India for early Alzheimer's disease at Rs91,688 per vial. The once-monthly therapy targets amyloid plaques and may help slow cognitive decline in eligible patients with mild symptoms.
-
FDA Approves New Weight-Loss Pill For Use At Any Time Of Day
The US regulator has approved Eli Lilly's new oral weight-loss drug Foundayo through a fast-track process, offering a more convenient and potentially affordable alternative to injectable obesity treatments.
-
'Once-A-Week Shot' Weight-Loss Drug Mounjaro Launched In India By Eli Lilly
Eli Lilly and Company (India) on Thursday said it has launched a first-of-its-kind medication for obesity and type 2 diabetes in the country after obtaining approval from the Central Drugs Standard Control Organisation (CDSCO).
-
Eli Lilly's Zepbound Drug Likely To Dominate Global Obesity Market: Report
Eli Lilly's Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic market expansion, a report showed on Tuesday.
-
US Drugmaker To Donate 400,000 Covid Treatment Tablets To India
Eli Lilly and Co said on Tuesday it would supply 400,000 tablets of its COVID-19 treatment, to be used with Gilead's remdesivir, to India as the country fights a raging pandemic that has morgues and hospitals overflowing.
-
US Allows Emergency Use Of First COVID-19 Antibody Drug
U.S. regulators on Monday authorized emergency use of the first experimental antibody drug for COVID-19 in patients who are not hospitalized but are at risk of serious illness because of their age or other conditions.
-
Eli Lilly Says Its Antibody Therapy May Reduce Covid Hospitalisations
Eli Lilly and Co.'s experimental antibody treatment for Covid-19 reduced the rate at which symptomatic patients were hospitalized compared to a placebo, according to preliminary study results released by the company and its partner.
-
Lilly's COVID-19 Drug Could Be Ready For Use As Soon As September
Eli Lilly and Co could have a drug specifically designed to treat COVID-19 authorized for use as early as September if all goes well with either of two antibody therapies it is testing, its chief scientist told Reuters on Wednesday.
-
Internet led to global 'explosion' of fake drugs
The rapid growth of Internet commerce has led to an explosion of counterfeit drugs sold around the world.
-
Eli Lilly Launches Alzheimer's Drug Lormalzi Priced At Rs 91,688 Per Vial In India
Eli Lilly has launched Lormalzi (donanemab) in India for early Alzheimer's disease at Rs91,688 per vial. The once-monthly therapy targets amyloid plaques and may help slow cognitive decline in eligible patients with mild symptoms.
-
FDA Approves New Weight-Loss Pill For Use At Any Time Of Day
The US regulator has approved Eli Lilly's new oral weight-loss drug Foundayo through a fast-track process, offering a more convenient and potentially affordable alternative to injectable obesity treatments.
-
'Once-A-Week Shot' Weight-Loss Drug Mounjaro Launched In India By Eli Lilly
Eli Lilly and Company (India) on Thursday said it has launched a first-of-its-kind medication for obesity and type 2 diabetes in the country after obtaining approval from the Central Drugs Standard Control Organisation (CDSCO).
-
Eli Lilly's Zepbound Drug Likely To Dominate Global Obesity Market: Report
Eli Lilly's Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic market expansion, a report showed on Tuesday.
-
US Drugmaker To Donate 400,000 Covid Treatment Tablets To India
Eli Lilly and Co said on Tuesday it would supply 400,000 tablets of its COVID-19 treatment, to be used with Gilead's remdesivir, to India as the country fights a raging pandemic that has morgues and hospitals overflowing.
-
US Allows Emergency Use Of First COVID-19 Antibody Drug
U.S. regulators on Monday authorized emergency use of the first experimental antibody drug for COVID-19 in patients who are not hospitalized but are at risk of serious illness because of their age or other conditions.
-
Eli Lilly Says Its Antibody Therapy May Reduce Covid Hospitalisations
Eli Lilly and Co.'s experimental antibody treatment for Covid-19 reduced the rate at which symptomatic patients were hospitalized compared to a placebo, according to preliminary study results released by the company and its partner.
-
Lilly's COVID-19 Drug Could Be Ready For Use As Soon As September
Eli Lilly and Co could have a drug specifically designed to treat COVID-19 authorized for use as early as September if all goes well with either of two antibody therapies it is testing, its chief scientist told Reuters on Wednesday.
-
Internet led to global 'explosion' of fake drugs
The rapid growth of Internet commerce has led to an explosion of counterfeit drugs sold around the world.
